BridgeBio Oncology Therapeutics, Inc.
BBOT
$7.40
-$0.29-3.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.53% | 13.32% | -57.40% | -28.93% | -12.03% |
| Total Depreciation and Amortization | -4.12% | 7.18% | 0.00% | 235.19% | 3.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 32.90% | -67.61% | 1,714.81% | -48.52% | 372.00% |
| Change in Net Operating Assets | 134.00% | -192.84% | 56.16% | 206.93% | -66.86% |
| Cash from Operations | 14.96% | -46.81% | -23.50% | -18.85% | -30.36% |
| Capital Expenditure | 67.12% | 47.86% | 39.39% | -42.59% | -1,520.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3,740.55% | -80.74% | 312.31% | -36.45% | -39.26% |
| Cash from Investing | -3,775.08% | -80.85% | 320.74% | -37.28% | -39.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 824.44% | -99.99% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 80.82% | 92.13% | -145.59% | -708.42% | -- |
| Cash from Financing | 150.34% | -100.16% | 1,827.81% | 4,792.08% | -876.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -815.81% | -109.29% | 7,014.73% | 214.39% | -143.84% |